Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KDventures ABLTS:0P3C 38 Buyback Yield % is -58.76 as of Jul. 15, 2026. GuruFocus rates LTS:0P3C with a GF Score™ of 38/100 and a GF Value™ of kr0.77 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 741 Biotechnology companies, KDventures AB ranks worse than 85.16% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for KDventures AB's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0P3C vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, KDventures AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KDventures AB Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, KDventures AB's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where KDventures AB's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KDventures AB (LTS:0P3C) has a Buyback Yield % of -58.76 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on KDventures AB and its competitors. According to the industry distribution chart, KDventures AB ranks #631 out of 741 companies in the Biotechnology industry, placing it in the top 85.2%.
Is KDventures AB's Buyback Yield % too high?
KDventures AB's current Buyback Yield % is -58.76. Based on the distribution chart, KDventures AB ranks #631 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, KDventures AB has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does KDventures AB's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, KDventures AB ranks #631 out of 741 companies for Buyback Yield %. This places KDventures AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on KDventures AB and its competitors. KDventures AB's current Buyback Yield % is -58.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KDventures AB stock overvalued right now?
Based on GuruFocus' analysis, KDventures AB (LTS:0P3C) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.77, compared to a current price of kr0.27 — trading 65.3% below its estimated fair value. The current Buyback Yield % is -58.76. KDventures AB's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For KDventures AB (LTS:0P3C), the current Buyback Yield % is -58.76 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KDventures AB (LTS:0P3C) Overvalued in 2026?
Based on GuruFocus' analysis, KDventures AB stock appears to be undervalued.
The current stock price of kr0.27 is trading 65.3% below its estimated GF Value™ of kr0.77.
GuruFocus considers KDventures AB to be Possible Value Trap.
Key valuation signals for LTS:0P3C:
Buyback Yield %: -58.76
GF Value™: kr0.77 vs. price of kr0.27 (65.3% below fair value)
No single metric tells the full story. See the LTS:0P3C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KDventures AB is a Nordic investment company specialized in life sciences. The company identifies and invests in pharmaceutical projects and medical technology products originating from research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, the company creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with value growth potential.
38GF Score
Get the complete analysis for LTS:0P3C
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0P3C has been successfully added to your 
